Generium And Selexis Debut Dornase Alfa In Russia
Generium is claiming the launch of the world’s first biosimilar version of Roche’s Pulmozyme after receiving approval for dornase alfa in Russia.
You may also be interested in...
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.
Russia’s Generium has announced its launch of the first biosimilar version of Alexion’s blockbuster orphan-disease drug Soliris, one of the most expensive prescription medicines in the world.
Selexis and Turgut have further expanded their biosimilar development partnership by signing commercial license agreements for two undisclosed biosimilar antibodies. Building on previous deals signed in July 2016 and December 2017, the companies are now working together to develop biosimilars to treat oncology and inflammatory diseases.